ARCT 250117 7.50C (ARCT250117C7500) Stock Options, News & Quotes

0.00
0.000.00%

15min DelayClose Jan 10 09:30 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

10baggerbamm

Jan 7 13:32

$Arcturus Therapeutics (ARCT.US)$at least I own one stock that's not going down today

10baggerbamm

Jan 7 08:55

$Arcturus Therapeutics (ARCT.US)$ hmm look what keeps going up... I posted this a few days ago you can go look this is a company that Bill gates's Bank rolling

10baggerbamm

Dec 29, 2024 00:16

$Arcturus Therapeutics (ARCT.US)$ this company is associated with Bill and Melinda Gates Foundation. they are in the process of developing a bird flu vaccination. the vaccine they're calling a pandemic injection.
out of California within the past couple of weeks you have Governor New scum talking about bird flu.. I've heard it mentioned on a couple of the fake news stations this past week. and now the self-proclaimed expert in medicine who believes that the world must be depopulated by 90% but i...

10baggerbamm OP : as a follow-up this is where you use options because you know exactly the risk going in you know what your loss is going to be.
unfortunately June of 25 is as far out as the contracts go. buying it out of the money contract and throwing a bid in which there's zero bid is what I'm going to do.. so I'll throw different bids in for a nickel $0, .10, .20 different amounts of contracts.. and see if I get filled

Report
Reply

Cancel Reply
10baggerbamm OP : additionally if you look at transactions in December you have acquisitions of stock by four parties within the company three are 60,000 shares one is 190,000 shares.
as they say people sell stock for variety of reasons but they buy stock for only one.

Report
Reply

Cancel Reply
10baggerbamm OP : 11/11/2024 - 04:01 PM
SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a “Study Can Proceed” notification for the Company’s Investigational New Drug (IND) application, ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine candidate for active immunization to prevent pandemic influenza disease caused by H5N1 virus. The clinical study is funded by Biomedical Advanced Research and Development Authority (BARDA) and designed to enroll approximately 200 healthy adults in the United States.

Report
Reply

Cancel Reply
10baggerbamm OP :

Report
Reply

Cancel Reply
10baggerbamm OP : https://expose-news.com/2024/12/18/self-replicating-vaccine-trial-in-the-usa/

Report
Reply

Cancel Reply

View more comments...

Laurence john tawil

May 28, 2024 10:16

$Arcturus Therapeutics (ARCT.US)$ wtf is happening bout to put this hoe down

Moomoo AI

Mar 9, 2024 06:57

Analysts maintain loss per share estimates for next year with no major changes to revenue estimates. However, the company's performance is expected to underperform the wider industry. The steady consensus price target indicates that reduced loss estimates may not positively impact the stock's long-term valuation.

Analysts Have Made A Financial Statement On Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Yearly Report